MMJ-002

MMJ-002 is a proprietary, cannabinoid-based investigational drug developed by MMJ International Holdings for the treatment of Huntington’s disease, specifically targeting chorea associated with the condition. The formulation contains highly purified cannabidiol (CBD) and tetrahydrocannabinol (THC), delivered as an oral gel capsule. Unlike recreational cannabis products, MMJ-002 is designed to provide therapeutic benefits without the psychoactive side effects typically associated with cannabis use. The drug has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA), which supports its development for rare diseases like Huntington’s disease and provides incentives such as marketing exclusivity and tax credits for clinical trials. A Phase 2 clinical trial is planned to evaluate its efficacy in mitigating involuntary movements in Huntington’s patients[1][3][4][6][7].